38 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am
finance, mergers and acquisitions, and business strategy
Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells … , corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
9 Oct 15
Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer
12:00am
, in particular, the corporate strategy, M&A, and business development of marketed and development stage in- and out-licensing.
”I’m thrilled to have … Terri join our executive team given her impressive global experience in corporate strategy, M&A, and business development,” said Colin Foster, President
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
8 Mar 22
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
8:03am
corporate strategy. We are pleased to be advancing this strategy with our latest patent, and look forward to further broadening our IP estate
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
in an effort to further expand the trial in Europe as part of its regulatory strategy. Due to the impact of COVID-19 pandemic on trial enrollment to-date … regulatory strategy. The enrollment of patients into the study in multiple Israeli sites to-date has been slower than originally anticipated, mainly due
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
inflammation, and an indication with a substantial unmet medical need that potentially represents a multibillion commercial market.
The revised strategy … revised strategy is targeted at obtaining topline data readouts from two advanced-stage clinical indications by mid-2025 – (a) a randomized
6-K
EX-99.1
hdkbyhnkvor koa
10 Nov 21
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
8:00am
6-K
EX-99.1
dvk3cccwux9y
7 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
8:01am
6-K
EX-99.1
9x9rfc2gww7e
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.1
yxopgei
2 Feb 15
Bio Blast Announces Key Leadership Changes
12:00am
6-K
pgbsycq5u 7v
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.1
ijc 3mxnhi66vegf2611
13 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
8:00am
6-K
EX-99.1
sp0h q8izsb6sm
23 May 22
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
8:03am
6-K
EX-99.1
aqa 66i17g
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
6-K
EX-99.3
7o1azo jux8l
19 Nov 18
Agreement and Plan of Merger
4:34pm
424B4
urt3jmom2t2d
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
pxbw2 sbhlan2
8 Jul 14
Registration statement (foreign) (amended)
12:00am
6-K
ldmrgc
27 Mar 19
Securities Purchase Agreement
8:32am
20-F
rcclwzz
31 Mar 15
Annual report (foreign)
12:00am
6-K
EX-99.1
geh8a
23 Sep 14
Notice of Extraordinary General Meeting of Shareholders
12:00am
6-K
EX-99.2
zkt1lz7m3iswypf1g
27 May 22
Condensed Consolidated Financial Statements
4:39pm